- Home
- INVA vs ANAB Comparison
INVA vs ANAB Comparison
Compare INVA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVA
- ANAB
- Stock Information
- Founded
- INVA 1996
- ANAB 2005
- Country
- INVA United States
- ANAB United States
- Employees
- INVA N/A
- ANAB N/A
- Industry
- INVA Biotechnology: Pharmaceutical Preparations
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- INVA Health Care
- ANAB Health Care
- Exchange
- INVA Nasdaq
- ANAB Nasdaq
- Market Cap
- INVA 1.1B
- ANAB 1.0B
- IPO Year
- INVA 2004
- ANAB 2017
- Fundamental
- Price
- INVA $18.23
- ANAB $36.00
- Analyst Decision
- INVA Buy
- ANAB Buy
- Analyst Count
- INVA 5
- ANAB 12
- Target Price
- INVA $35.60
- ANAB $63.30
- AVG Volume (30 Days)
- INVA 718.0K
- ANAB 344.1K
- Earning Date
- INVA 11-05-2025
- ANAB 11-04-2025
- Dividend Yield
- INVA N/A
- ANAB N/A
- EPS Growth
- INVA N/A
- ANAB N/A
- EPS
- INVA 0.53
- ANAB N/A
- Revenue
- INVA $370,229,000.00
- ANAB $169,467,000.00
- Revenue This Year
- INVA $7.98
- ANAB $37.52
- Revenue Next Year
- INVA $11.60
- ANAB N/A
- P/E Ratio
- INVA $34.20
- ANAB N/A
- Revenue Growth
- INVA 12.02
- ANAB 196.42
- 52 Week Low
- INVA $16.52
- ANAB $12.21
- 52 Week High
- INVA $22.00
- ANAB $39.78
- Technical
- Relative Strength Index (RSI)
- INVA 54.24
- ANAB 65.98
- Support Level
- INVA $17.45
- ANAB $35.82
- Resistance Level
- INVA $18.31
- ANAB $37.08
- Average True Range (ATR)
- INVA 0.50
- ANAB 1.83
- MACD
- INVA 0.15
- ANAB -0.32
- Stochastic Oscillator
- INVA 66.27
- ANAB 44.20
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).